AI Drug Discovery for Pharma and Biotech

Drug discovery

5

drugs

With orphan designations

Overview

Lymphangioleiomyomatosis (LAM) is a rare, progressive multisystem neoplasm characterized by cystic lung destruction, lymphatic abnormalities, and renal angiomyolipomas. Driven by TSC1/TSC2 mutations causing mTOR pathway dysregulation, it predominantly affects women of reproductive age. Key features include dyspnea, recurrent pneumothoraces, chylous effusions, and progressive respiratory decline. Diagnosis relies on high-resolution CT, VEGF-D testing, and genetic evaluation. mTOR inhibitors (e.g., sirolimus) stabilize lung function and reduce complications [7].

Population

Affects ~3.4–26.04 per million women, with higher prevalence in TSC-associated cases (30–40% of women with tuberous sclerosis). Sporadic LAM typically occurs in premenopausal women (mean age 34 years) [1][3][9][15].

Burden

  • 50–80% experience pneumothorax (recurrent in most), 20–30% develop chylous complications [3][4][19].

  • Progressive lung function decline (FEV1 loss: 75–120 mL/year) [5][19].

  • 10-year survival ~70%, with respiratory failure as the leading cause of mortality [3][4].

  • Significant quality-of-life impact due to dyspnea, fatigue, and frequent interventions [2][6].

Therapies

  • mTOR inhibitors: Sirolimus stabilizes lung function, reduces angiomyolipoma size, and resolves chylous effusions [2][6][10].

  • Pneumothorax management: Early pleurodesis (reduces recurrence from >70% to ~30%) [5][6].

  • Advanced care: Oxygen therapy, pulmonary rehabilitation, and lung transplantation (post-transplant survival ~12 years) [6][13].

Categories: rare genetic diseases, rare respiratory diseases, rare transplant-related disorders

Research Papers

675 drug discovery papers related to Lymphangioleiomyomatosis, with 5 first-in-class and 5 next-in-class early-stage therapies forecasted to outperform the average preclinical success rate. Recent publications:

675 drug discovery papers related to Lymphangioleiomyomatosis, with 5 first-in-class and 5 next-in-class early-stage therapies forecasted to outperform the average preclinical success rate. Recent publications:

2026-07-02 | Robot-Assisted Lobectomy for Lung Cancer Complicated by Lymphangioleiomyomatosis.

Lymphangioleiomyomatosis (LAM) is a rare systemic disease characterized by progressive cystic destruction of the lung parenchyma, resulting in extreme parenchymal fragility. Surgical treatment of lung cancer in patients with LAM is technically challenging due to the high risk of intractable air leaks. We report a case of robot-assisted thoracoscopic surgery (RATS) for lung cancer in a patient with LAM, highlighting a strategic hybrid approach to managing the exceptionally fragile lung tissue. A 56-year-old woman with tuberous sclerosis complex-associated LAM was diagnosed with Stage IA1 adenocarcinoma in the left upper lobe. We performed a RATS left upper lobectomy using the da Vinci Xi system (Intuitive Surgical, Sunnyvale, CA, USA). To protect the exceptionally fragile lung, a "no-touch" retraction technique was employed using rolled gauze and blunt-tipped robotic instruments. A fissureless technique was applied to minimize parenchymal injury. Crucially, for the division of the incomplete interlobar fissure and the bronchus, we utilized manual staplers equipped with bioabsorbable reinforcement material (buttressed staplers) deployed by a bedside assistant, which provided superior sealing for the fragile lung compared to the robotic staplers available at that time. Despite these precautions, a pinhole air leak occurred in the S8 segment, likely due to unintentional contact with a robotic joint, illustrating the extreme sensitivity of the LAM lung. This was identified via a meticulous sealing test and repaired with polyglycolic acid sheets and fibrin glue. The patient was discharged on POD 5 without persistent air leaks. At 1 year post-surgery, her respiratory function was well-preserved, exceeding predicted values. RATS offers superior visualization for lung cancer surgery in patients with LAM. However, given the extreme fragility of the lung, the selective use of manual buttressed staplers is a vital adjunct to prevent postoperative air leaks. Optimal outcomes depend on a constant awareness of lung fragility, a hybrid technical strategy, and a rigorous intraoperative sealing test to identify and repair even minor pleural injuries.

Open article ↗



2026-06-30 | Exploring glucocorticoid receptor signalling in lymphangioleiomyomatosis.

Lymphangioleiomyomatosis (LAM) is a rare, low-grade neoplasm that causes progressive cystic lung destruction and is often associated with renal angiomyolipomas (AMLs). Given evidence of pleiotropy linking LAM risk to pulmonary traits, we investigated whether glucocorticoid receptor (GR) signalling might influence LAM biology and clinical features. We combined cell-based studies, GR inhibition/activation assays, gene expression and single-cell RNA sequencing analyses, and hormone profiling in retrospective and prospective LAM cohorts. Cellular experiments employed murine Tsc2 -/- embryonic fibroblasts and human TSC2 -/- AML cells. Circulating steroid levels were measured in women with LAM and healthy controls, and associations with clinical variables were evaluated. In LAM/AML models, GR activation by glucocorticoids elicited transcriptional responses, whereas GR inhibition reduced clonogenic potential. GR stimulation was associated with CDKN1C upregulation through enhancer binding, and single-cell profiling suggested a shift towards slower proliferation and differentiation-prone states enriched for a LAM cell signature. Clinically, our analyses suggest that women with LAM may show altered circulating hormone profiles, including elevated adrenocorticotropic hormone (ACTH) and cortisol levels, together with reduced 17-hydroxyprogesterone, compared with controls. In a prospective cohort, ACTH levels were suggestively associated with advanced radiological disease stage. AML cells showed elevated expression of POMC, which encodes the precursor of ACTH, and POMC peptide was detected in LAM lung tissue. Our findings suggest that GR signalling may contribute to aspects of LAM cell behaviour and disease status. Further investigation of this pathway could clarify its role as a disease modifier and potential therapeutic target.

Open article ↗



2026-07-02 | Robot-Assisted Lobectomy for Lung Cancer Complicated by Lymphangioleiomyomatosis.

Lymphangioleiomyomatosis (LAM) is a rare systemic disease characterized by progressive cystic destruction of the lung parenchyma, resulting in extreme parenchymal fragility. Surgical treatment of lung cancer in patients with LAM is technically challenging due to the high risk of intractable air leaks. We report a case of robot-assisted thoracoscopic surgery (RATS) for lung cancer in a patient with LAM, highlighting a strategic hybrid approach to managing the exceptionally fragile lung tissue. A 56-year-old woman with tuberous sclerosis complex-associated LAM was diagnosed with Stage IA1 adenocarcinoma in the left upper lobe. We performed a RATS left upper lobectomy using the da Vinci Xi system (Intuitive Surgical, Sunnyvale, CA, USA). To protect the exceptionally fragile lung, a "no-touch" retraction technique was employed using rolled gauze and blunt-tipped robotic instruments. A fissureless technique was applied to minimize parenchymal injury. Crucially, for the division of the incomplete interlobar fissure and the bronchus, we utilized manual staplers equipped with bioabsorbable reinforcement material (buttressed staplers) deployed by a bedside assistant, which provided superior sealing for the fragile lung compared to the robotic staplers available at that time. Despite these precautions, a pinhole air leak occurred in the S8 segment, likely due to unintentional contact with a robotic joint, illustrating the extreme sensitivity of the LAM lung. This was identified via a meticulous sealing test and repaired with polyglycolic acid sheets and fibrin glue. The patient was discharged on POD 5 without persistent air leaks. At 1 year post-surgery, her respiratory function was well-preserved, exceeding predicted values. RATS offers superior visualization for lung cancer surgery in patients with LAM. However, given the extreme fragility of the lung, the selective use of manual buttressed staplers is a vital adjunct to prevent postoperative air leaks. Optimal outcomes depend on a constant awareness of lung fragility, a hybrid technical strategy, and a rigorous intraoperative sealing test to identify and repair even minor pleural injuries.

Open article ↗



2026-06-30 | Exploring glucocorticoid receptor signalling in lymphangioleiomyomatosis.

Lymphangioleiomyomatosis (LAM) is a rare, low-grade neoplasm that causes progressive cystic lung destruction and is often associated with renal angiomyolipomas (AMLs). Given evidence of pleiotropy linking LAM risk to pulmonary traits, we investigated whether glucocorticoid receptor (GR) signalling might influence LAM biology and clinical features. We combined cell-based studies, GR inhibition/activation assays, gene expression and single-cell RNA sequencing analyses, and hormone profiling in retrospective and prospective LAM cohorts. Cellular experiments employed murine Tsc2 -/- embryonic fibroblasts and human TSC2 -/- AML cells. Circulating steroid levels were measured in women with LAM and healthy controls, and associations with clinical variables were evaluated. In LAM/AML models, GR activation by glucocorticoids elicited transcriptional responses, whereas GR inhibition reduced clonogenic potential. GR stimulation was associated with CDKN1C upregulation through enhancer binding, and single-cell profiling suggested a shift towards slower proliferation and differentiation-prone states enriched for a LAM cell signature. Clinically, our analyses suggest that women with LAM may show altered circulating hormone profiles, including elevated adrenocorticotropic hormone (ACTH) and cortisol levels, together with reduced 17-hydroxyprogesterone, compared with controls. In a prospective cohort, ACTH levels were suggestively associated with advanced radiological disease stage. AML cells showed elevated expression of POMC, which encodes the precursor of ACTH, and POMC peptide was detected in LAM lung tissue. Our findings suggest that GR signalling may contribute to aspects of LAM cell behaviour and disease status. Further investigation of this pathway could clarify its role as a disease modifier and potential therapeutic target.

Open article ↗



Access all drug discovery articles and probability of success in trials forecasts:

Access all drug discovery articles and probability of success in trials forecasts:

Drug Discovery Landscape

5 orphan drug designations for Lymphangioleiomyomatosis, including 1 approved therapy.

5 orphan drug designations for Lymphangioleiomyomatosis, including 1 approved therapy.

Drug

Therapy type

Regulator

Orphan designation

Approval

Sponsor

Sirolimus

small molecules

EMA

2016-07-14

Maxia Strategies-Europe Limited

sirolimus

small molecules

FDA

2014-11-17

Cote Orphan Consulting, LLC

sirolimus

small molecules

FDA

2014-06-25

LAM Therapeutics, Inc.

sirolimus [Rapamune]

small molecules

FDA

2012-10-31

2015-05-28

Pfizer, Inc.

Quinacrine hydrochloride

small molecules

FDA

1984-10-17

Lyphomed, Inc.

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.